Silke Gillessen joins the podcast to discuss the top areas of consensus and controversy from APCCC 2025. ...
The Uromigos
The Uromigos, Thomas Powles, MD, and Brian Rini, MD, FASCO, highlight the latest developments in genitourinary cancers. Each podcast episode features a guest expert from around the world discussing the latest data, debates, and manuscripts relevant to the practical clinical care of GU oncology patients.
Latest Episode
Advertisement
Dr. Tyler Seibert provides updates from the 2025 APCC Diagnostics conference.
Dr. Silke Gillessen joins the show to discuss some of the top highlights from this year's ASCO GU conference.
Returning guest Dr. Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.
Dr. Vincent Xu of Dana-Farber Cancer Institute discusses this emerging RCC biomarker and data from the Checkmate 214 trial.
Returning guest Dr. Laurence Albiges discusses novel combos in refractory RCC and gives an update on COSMIC-313.
Dr. Gopa Iyer of Memorial Sloan Kettering Cancer Center joins the show to discuss his initial results.
Advertisement
The Uromigos: Live and Unplugged 2023
Dr. Powles chaired a livestreamed RCC session that included lively discussion from Drs. Atkins, McDermott, and Rini.
The panel highlights a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2.
The panel discusses data related to RLTs in prostate cancer, including a recap of the VISION trial and the PSMAfore trial.
The panel breaks down the details of the PROpel, TALAPRO-2, and MAGNITUDE trials along with relevant rPFS and HR data.
Kidney Cancer Discussions
Returning guest Dr. Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.
Dr. Vincent Xu of Dana-Farber Cancer Institute discusses this emerging RCC biomarker and data from the Checkmate 214 trial.
Returning guest Dr. Laurence Albiges discusses novel combos in refractory RCC and gives an update on COSMIC-313.
David Braun, MD, PhD joins the show to discuss his Nature paper on a personalized RCC vaccine.
Dr. Brian Rini’s Disclosures
Research Funding to Institution: Pfizer, Hoffman-LaRoche, Incyte, AstraZeneca, Taris, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, BMS, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, Exelixis
Consulting: BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Compugen, Merck, Corvus, Surface Oncology, 3DMedicines, Aravive, Alkermes, Arrowhead, GSK, Shionogi, Eisai
Stock: PTC therapeutics
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.